Rapport Therapeutics announced on April 1 2026 that it will present new Phase 2a follow‑up data for its lead epilepsy candidate RAP‑219 at the American Academy of Neurology (AAN) Annual Meeting in Chicago. The presentation is scheduled for April 21 2026 at 3:54 PM CDT, during the conference’s April 18‑22 window.
The presentation will cover an 8‑week follow‑up period of the Phase 2a trial in patients with focal onset seizures, building on the September 8 2025 topline results that showed a 77.8% reduction in clinical seizures and 24% seizure freedom. The data are expected to reinforce the company’s claim of best‑in‑class efficacy.
The new data represent a key clinical milestone that will inform the design of two planned Phase 3 trials slated to begin in Q3 2026. Positive follow‑up results could accelerate regulatory discussions and strengthen investor confidence in RAP‑219’s path to market.
Dr. Jeffrey Sevigny, Chief Medical Officer, said, “These additional results build upon the robust efficacy data we observed in the Phase 2a trial and further expand the growing body of evidence supporting RAP‑219’s potential as a best‑in‑class anti‑seizure medication for patients with drug‑resistant focal onset seizures.” The company also highlighted its long‑acting injectable formulation and broader pipeline in bipolar mania and peripheral neuropathic pain.
Rapport’s RAP‑219 targets a $2.5 billion opportunity in refractory focal‑onset seizures alone, and the company’s Phase 2a success has already attracted analyst upgrades and a $44.00 price target from Truist Securities. The upcoming presentation will be closely watched by clinicians and investors alike as a barometer of the drug’s clinical trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.